How do you advise patients on duration of first line maintenance PARPi and the potential risk of MDS or AML?
Is MDS/AML risk increased with longer duration of therapy? Does your approach differ for patients who are BRCA+/HRD vs wild type/HRP?
Answer from: at Academic Institution
For patients, who could derive significant survival benefit from first line maintenance PARP-inhibition (BRCA+ and HRD tumors), we advise them to take PARP-inhibitors up to 2 years (olaparib) or up to 3 years (niraparib) if no disease progression or unacceptable toxicity. I counsel patients that dev...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Olaparib, with or without bevacizumab, has regulatory approval in the United States by the FDA for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced EOC who are in complete or partial response to first-line platinum-based ...